MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00011-021-01507-5

Медицинская библиотека · Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.

Lomakin Nikita V, Bakirov Bulat A, Protsenko Denis N, Mazurov Vadim I, Musaev Gaziyavdibir H, Moiseeva Olga M, Pasechnik Elena S, Popov Vladimir V, Smolyarchuk Elena A, Gordeev Ivan G, Gilyarov Mikhail Yu, Fomina Darya S, Seleznev Anton I, Linkova Yulia N, Dokukina Ekaterina A, Eremeeva Anna V, Pukhtinskaia Polina S, Morozova Maria A, Zinkina-Orikhan Arina V, Lutckii Anton A

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVE AND

DESIGN

The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19.

SUBJECTS: The study included 217 patients. The eligible were men and non-pregnant women aged 18 years or older, hospitalized for severe COVID-19 pneumonia.

TREATMENT: 206 subjects were randomized (1:1) to receive single subcutaneous administration of LVL 324 mg or placebo, both in combination with standard of care (SOC). 204 patients received allocated therapy. After the LVL/placebo administration in case of deterioration of symptoms, the investigator could perform a single open-label LVL 324 mg administration as the rescue therapy.

METHODS

The primary efficacy endpoint was the proportion of patients with sustained clinical improvement on the 7-category ordinal scale on Day 14. All efficacy data obtained after rescue therapy administration were considered missing. For primary efficacy analysis, all subjects with missing data were considered non-responders.

RESULTS

63.1% and 42.7% of patients in the LVL and in the placebo groups, respectively, achieved sustained clinical improvement on Day 14 (P = .0017). The frequency of adverse drug reactions was comparable between the groups.

CONCLUSION

In patients with radiologically confirmed SARS-CoV-2 pneumonia, requiring or not oxygen therapy (but not ventilation) with no signs of other active infection administration of LVL + SOC results in an increase of sustained clinical improvement rate.

TRAIL REGISTRATION: The trial is registered at the US National Institutes of Health (ClinicalTrials.gov; NCT04397562).

Для цитирования: Lomakin Nikita V, Bakirov Bulat A, Protsenko Denis N, Mazurov Vadim I, Musaev Gaziyavdibir H, Moiseeva Olga M, Pasechnik Elena S, Popov Vladimir V, Smolyarchuk Elena A, Gordeev Ivan G, Gilyarov Mikhail Yu, Fomina Darya S, Seleznev Anton I, Linkova Yulia N, Dokukina Ekaterina A, Eremeeva Anna V, Pukhtinskaia Polina S, Morozova Maria A, Zinkina-Orikhan Arina V, Lutckii Anton A. The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. 2021. DOI: 10.1007/s00011-021-01507-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.